CogState Signs Contract For Phase 2 Schizophrenia Study
Filed with ASX ·
Watch Cogstate's latest callCogstate (ASX:CGS) Q4 2026 Earnings Call · Replay · Aug 17Read the transcript of Cogstate (ASX:CGS) Q4 2026 Earnings Call6ix hasn’t read this filing yet.
Story so far
Earlier from Cogstate
- Merck releases new data on effectiveness of Cognigram
- Growing recognition of Cogstate test as a cognitive tool
- CogState launches Cognigram test in Canada
- Fully Underwritten Non-Renounceable Rights Issue / Placement
- Business Update and First Half Financial Guidance
Later from Cogstate
- Business Update - Unaudited Full Year Profit Results
- CogState Again Used in Successful Schizophrenia Study
- CogState announces partnership in area of cognitive training
- CogState Tests Used in Successful Ph 2 Schizophrenia Study
- Growth in sales contracts delivers strong Q1 results
Follow Cogstate into a list and get an email when it puts out news.
Follow Cogstate